SCHEMBL1371575

SCHEMBL1371575

[CH2]N1CCC(N2CCOCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL3 Q96JM7 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
OPRL1 P41146 2/20 0.38
HPGD P15428 2/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 4/20 0.36
CYP2A13 Q16696 1/20 0.35
LMNA P02545 1/20 0.35
KDM1A O60341 1/20 0.35
MAOB P27338 1/20 0.35
EPHX2 P34913 1/20 0.33
HSD11B1 P28845 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26112782 0.82 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
SCHEMBL3168997 0.82
SCHEMBL26112778 0.82 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
SCHEMBL16877830 0.80
SCHEMBL14862483 0.79 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
Ammonia Solution, Strong SCHEMBL4295582 0.79 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
SCHEMBL9425142 0.77 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
SCHEMBL1372142 0.77 L3MBTL3 (0.48) L3MBTL3L3MBTL1KDM4E
SCHEMBL1827648 0.77 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD
SCHEMBL23436477 0.76 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL3L3MBTL1OPRL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861605-B1 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders DART NEUROSCIENCE (CAYMAN) LTD (KY) 2017-05-03 EP claimed
US-9499562-B2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2016-11-22 US claimed
US-20160031901-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS DART NEUROSCIENCE LLC 2016-02-04 US claimed
US-7897778-B2 Benzamide compounds ASTRAZENECA (SE) 2011-03-01 US claimed
US-20080293687-A1 Benzamide Compounds ASTRAZENECA AB (SE) 2008-11-27 US claimed
WO-2006024841-A2 BENZAMIDE COMPOUNDS ASTRAZENECA AB (SE) 2006-03-09 WO claimed
EP-3781574-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2021-02-24 EP disclosed
WO-2020147802-A1 MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-23 WO disclosed
US-10092575-B2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2018-10-09 US disclosed
US-20170209459-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS DART NEUROSCIENCE LLC 2017-07-27 US disclosed
EP-2861605-B1 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders DART NEUROSCIENCE (CAYMAN) LTD (KY) 2017-05-03 EP disclosed
US-9499562-B2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2016-11-22 US disclosed
US-20160031901-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS DART NEUROSCIENCE LLC 2016-02-04 US disclosed
US-7112594-B2 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-09-26 US disclosed
US-7015218-B1 Amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-03-21 US disclosed
WO-2006024841-A2 BENZAMIDE COMPOUNDS ASTRAZENECA AB (SE) 2006-03-09 WO disclosed
EP-1176140-B1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2004-12-29 EP disclosed
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-10-30 US disclosed
EP-1310488-A1 FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-14 EP disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10092575-B2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds TPMT, PSEN2, GRIN2C SMN1; SMN2 104/4885L3MBTL3 3602/4885L3MBTL1 2789/4885
US-20030203909-A1 Fused bicyclic amide compounds and medicinal use thereof BET1, NFATC1, ARG1 SMN1; SMN2 4550/4885L3MBTL3 2498/4885L3MBTL1 1711/4885
US-20160031901-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS TPMT, PSEN2, GRIN2C SMN1; SMN2 132/4885L3MBTL3 3330/4885L3MBTL1 2686/4885
US-20080293687-A1 Benzamide Compounds HDAC1, HDAC11, HDAC2 SMN1; SMN2 1455/4885L3MBTL3 914/4885L3MBTL1 864/4885
US-20170209459-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS TPMT, PSEN2, GRIN2C SMN1; SMN2 104/4885L3MBTL3 3602/4885L3MBTL1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.